Hematology Analyzers and Reagents Market Growth Forecast
Analysis based on 6 articles · First reported Jul 08, 2026 · Last updated Aug 20, 2026
The positive growth forecasts signal expanding demand for hematology diagnostic equipment and reagents, benefiting manufacturers and suppliers. Investors may see upside in companies with strong positions in this market, particularly those innovating with automation and AI.
Multiple market research reports project significant growth in the global hematology analyzers and reagents market over the next several years. MarketsandMarkets forecasts growth from USD 7.57 billion in 2026 to USD 10.33 billion by 2031, a CAGR of 6.4%. The Business Research Company projects the market to reach $5.66 billion by 2030 (CAGR 6.8%) for analyzers and $7.19 billion by 2030 (CAGR 8.1%) for analyzers and reagents. Coherent Market Insights also published a study covering 2026-2033. Growth is driven by rising prevalence of blood disorders, adoption of advanced diagnostic technologies, laboratory automation, and AI-based cell analysis. The blood cancer segment dominates applications, and MSCI Asia Pacific Index is the fastest-growing region. Key players include Sysmex Corporation, Danaher Corporation, Nihon Kohden Corporation, Siemens — Siemens Healthineers, Abbott Laboratories, and others. Notable recent developments include Mars Inc.'s acquisition of Mars, Incorporated — Heska Corporation for $1.3 billion in June 2023, Horiba's introduction of the HELO 2.0 and Yumizen Helo automated platforms in January 2024, and Fujirebio' partnership with Agappe Diagnostics in January 2024.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard